Skip to Content

Press Release

Result of AGM

June 25, 2018 at 7:00 AM BST

Released : Jun 25, 2018

RNS Number : 4587S
Tiziana Life Sciences PLC
25 June 2018

Tiziana Life Sciences plc
(the "Company")

Results of Annual General Meeting

At the Annual General Meeting of the Company held at 10.00 a.m. on Monday 25 June 2018 all the resolutions proposed were duly passed.

Details of the proxy voting at the Annual General Meeting will be posted to the Company's website later today.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

For more information go to


Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder 

+44 (0)20 7493 2853

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner 

+44 (0)20 7213 0883

Stockdale Securities (Broker)

Andy Crossley / Antonio Bossi


+44 (0)20 7601 6125


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit